Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad

AMA J Ethics. 2016 Jul 1;18(7):727-35. doi: 10.1001/journalofethics.2016.18.7.pfor1-1607.

Abstract

The Trans-Pacific Partnership (TPP) Agreement is a proposed free trade agreement between the US and 11 other countries in Asia and South America covering many consumer goods, including prescription medicines. This review describes how the TPP could affect international laws governing intellectual property rights for prescription drugs, focusing on patents and exclusivity protections for test data, including their effect on reimbursement decisions by national health care authorities responsible for health priority setting. We conclude that the TPP could affect low-income patients' access to medicines in signatory countries.

MeSH terms

  • Asia
  • Commerce / legislation & jurisprudence*
  • Drug Costs
  • Drug Industry / legislation & jurisprudence*
  • Health Services Accessibility / economics*
  • Humans
  • Insurance, Health, Reimbursement
  • Intellectual Property*
  • International Cooperation / legislation & jurisprudence*
  • Patents as Topic / legislation & jurisprudence*
  • Poverty
  • Prescription Drugs / economics
  • Research / legislation & jurisprudence*
  • South America
  • United States

Substances

  • Prescription Drugs